一致B(200028) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached CNY 18.69 billion, an increase of 8.96% compared to CNY 17.15 billion in the same period last year[5] - Net profit attributable to shareholders was CNY 362.21 million, reflecting a year-on-year growth of 43.53% from CNY 252.36 million[5] - The net profit after deducting non-recurring gains and losses was CNY 351.79 million, up 45.22% from CNY 242.24 million year-on-year[5] - Basic earnings per share increased by 44.07% to CNY 0.85 from CNY 0.59 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 18,686,817,786.50, an increase of 8.93% compared to CNY 17,150,856,946.54 in Q1 2022[20] - Operating costs for Q1 2023 amounted to CNY 18,166,841,198.40, up from CNY 16,797,706,856.47 in the same period last year, reflecting a growth of 8.14%[20] - Net profit for Q1 2023 reached CNY 460,830,788.65, representing a 56.36% increase from CNY 294,771,604.63 in Q1 2022[21] - Operating profit increased by CNY 201.27 million, a growth rate of 53.66%, mainly due to expanded sales scale and optimized business structure, leading to an increase in gross profit margin[11] - Net profit increased by CNY 166.06 million, a growth rate of 56.33%, driven by expanded sales scale and improved business structure[20] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 209.99 million, a significant turnaround from a negative cash flow of CNY 217.45 million in the previous year[5] - Cash flow from operating activities increased by CNY 427.44 million, a growth rate of 196.57%, due to adjustments in settlement methods and cycles[32] - The company's cash flow from operating activities showed a significant improvement, contributing positively to the overall financial health[22] - Total cash inflow from operating activities was 15,723,524,491.66 CNY, down 7.0% from 16,903,855,556.67 CNY in the prior period[23] - Cash outflow from operating activities decreased to 15,513,539,023.33 CNY from 17,121,307,780.05 CNY, reflecting a reduction of 9.4%[23] - The net cash flow from investing activities was -69,033,448.77 CNY, an improvement from -94,260,921.92 CNY in the previous period[24] - Cash inflow from financing activities totaled 566,164,144.13 CNY, down 25.1% from 755,291,223.35 CNY in the prior period[24] - The net cash flow from financing activities was -82,583,637.41 CNY, compared to a positive 112,007,819.57 CNY in the previous period[24] - The ending balance of cash and cash equivalents was 5,500,542,685.89 CNY, an increase from 4,533,806,395.75 CNY in the prior period[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 47.89 billion, representing a 12.36% increase from CNY 42.62 billion at the end of the previous year[5] - The company's total assets increased to CNY 47,885,197,936.57 in Q1 2023, compared to CNY 42,615,760,577.42 in Q1 2022, marking a growth of 12.67%[19] - Total liabilities rose to CNY 27,998,280,101.09 in Q1 2023, up from CNY 23,171,053,907.57 in Q1 2022, indicating a 20.00% increase[19] - The total current assets as of March 31, 2023, amounted to CNY 36,929,433,752.58, an increase from CNY 31,708,246,272.74 at the beginning of the year, representing a growth of approximately 16.9%[17] Shareholder Information - The company reported a total of 10 major shareholders, with the largest being China National Pharmaceutical Group holding 56.06% of shares[15] - The company has a total of 239,999,991 shares held by China National Pharmaceutical Group, which is subject to limited sale conditions[15] - The total number of shares held by the top 10 unrestricted shareholders is 234,494,221[15] Research and Development - Research and development expenses doubled to CNY 222.98 million, reflecting the company's investment in medical management and smart service platform development[10] - Research and development expenses were recorded at CNY 2,229,800.69, highlighting the company's commitment to innovation[20] Market Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research initiatives[16] - The financial report indicates a strategic emphasis on improving liquidity and managing receivables effectively to support future growth[16]